BridgeBio Pharma Debt Issuance/Retirement Net - Total 2018-2025 | BBIO
BridgeBio Pharma annual/quarterly debt issuance/retirement net - total history and growth rate from 2018 to 2025. Debt issuance/retirement net - total can be defined as the total amount of short term and long term borrowings repaid and issued.
- BridgeBio Pharma debt issuance/retirement net - total for the quarter ending March 31, 2025 was $116M, a 595.37% decline year-over-year.
- BridgeBio Pharma debt issuance/retirement net - total for the twelve months ending March 31, 2025 was $0.018B, a 177.88% decline year-over-year.
- BridgeBio Pharma annual debt issuance/retirement net - total for 2024 was $-0.051B, a 0% decline from 2023.
- BridgeBio Pharma annual debt issuance/retirement net - total for 2023 was $0B, a 100% decline from 2022.
- BridgeBio Pharma annual debt issuance/retirement net - total for 2022 was $-0.02B, a 101.9% decline from 2021.
BridgeBio Pharma Annual Debt Issuance/Retirement Net - Total
(Millions of US $) |
| 2024 |
$-51 |
| 2023 |
$N/A |
| 2022 |
$-20 |
| 2021 |
$1,080 |
| 2020 |
$550 |
| 2019 |
$37 |
| 2018 |
$56 |
| 2017 |
$4 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.426B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
